扩展至18周岁以上人群！GSK带状疱疹疫苗在华获批新适应症

Core Insights - GSK's recombinant shingles vaccine, RZV, has been approved by China's NMPA for use in adults aged 18 and above who are at increased risk of shingles due to known diseases or treatments that cause immunodeficiency or immunosuppression [1][2] - The approval addresses a significant public health issue, as there are approximately 6 million cases of shingles in China each year, with factors like immunodeficiency increasing the risk of infection [1] - This is the first and only recombinant shingles vaccine approved for this high-risk population in China, filling a critical gap in disease prevention [2] Company Strategy - GSK aims to enhance the accessibility of RZV for high-risk groups, recognizing the severe impact shingles can have on their health and quality of life [2] - The company is committed to integrating disease prevention into its corporate strategy, supporting the development of a comprehensive "prevention-treatment" solution throughout the lifecycle of healthcare [2] - GSK's efforts align with China's vision for "Healthy China 2030," contributing to the advancement of immunization initiatives in the country [2] Clinical Evidence - The approval was based on data from six clinical trials conducted in patients aged 18 and older, including those who have recently undergone hematopoietic stem cell transplants, kidney transplants, or are living with blood cancers, solid tumors, or HIV [2]